Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Oct 20, 2026

Revelation Biosciences, Inc. (REVB)

A forensic read on Revelation Biosciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Distress

Financial health

-10.8

Distress distance

Clean

Earnings quality

Forensic signals

-131.4%

ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Revelation Biosciences, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -10.8, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+560.1%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +4258% over the last 2 years to FY2025 (+560.1%/yr). The count is growing — 0.0M shares in FY2023, 0.6M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~560.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~98%.

-$33.9M

FY2023–FY2025

Cash burn vs. reported loss. Over FY2023–FY2025, the company reported a cumulative net loss of $24.1M against operating cash flow of -$33.9M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.

Key fundamentals

Return on Equity-131.4%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Revelation Biosciences, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Oct 20, 2026. Forensic signals flag probability, not certainty.